$57.1M in CY2024 Part D spend3K claims · 1K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Tildrakizumab-Asmn used for?
Tildrakizumab-Asmn is a Interleukin-23 Antagonist medication tracked in Medicare Part D.
Is there a generic for Tildrakizumab-Asmn?
No. Tildrakizumab-Asmn is brand-only with no generic equivalents currently in market.
How much does my plan pay for Tildrakizumab-Asmn?
NADAC pricing data not currently available for this drug.
Is Tildrakizumab-Asmn on the FDA shortage list?
No. Tildrakizumab-Asmn is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.